U.S. markets closed
  • S&P 500

    3,298.46
    +51.87 (+1.60%)
     
  • Dow 30

    27,173.96
    +358.52 (+1.34%)
     
  • Nasdaq

    10,913.56
    +241.29 (+2.26%)
     
  • Russell 2000

    1,474.91
    +23.09 (+1.59%)
     
  • Crude Oil

    40.14
    -0.17 (-0.42%)
     
  • Gold

    1,865.90
    -11.00 (-0.59%)
     
  • Silver

    23.03
    -0.17 (-0.72%)
     
  • EUR/USD

    1.1632
    -0.0043 (-0.37%)
     
  • 10-Yr Bond

    0.6590
    -0.0070 (-1.05%)
     
  • GBP/USD

    1.2745
    -0.0007 (-0.05%)
     
  • USD/JPY

    105.5760
    +0.1740 (+0.17%)
     
  • BTC-USD

    10,748.58
    -12.00 (-0.11%)
     
  • CMC Crypto 200

    230.00
    +12.17 (+5.59%)
     
  • FTSE 100

    5,842.67
    +19.89 (+0.34%)
     
  • Nikkei 225

    23,204.62
    +116.80 (+0.51%)
     

QIAGEN Expands Integrated Coronavirus NGS and Software Solutions to Accelerate COVID-19 Research

  • QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing

  • QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) launched the innovative QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome, along with integrated analysis and interpretation workflows for insights into the evolution and spread of the virus that causes COVID-19 disease. The new products are an expansion of QIAGEN’s broad offering of sample technologies, diagnostic tests and instruments, and research tools for use in the global effort to combat the COVID-19 pandemic.

"These solutions aim to accelerate research into COVID-19 prevention and treatment by enabling deeper, more holistic insights into the biology of SARS-CoV-2. The more we understand the novel coronavirus and its development, the better equipped the world will be to stop the pandemic," said Thierry Bernard, Chief Executive Officer of QIAGEN. "We are partnering with leading institutes and companies to accelerate this vital research. Our new QIAseq SARS-CoV-2 Primer Panel and software pipeline will guide researchers into insights on the epidemiology, metatranscriptomics, immune response and pathways of the coronavirus – contributing to drug and vaccine development and public health strategies."

QIAGEN’s new QIAseq SARS-CoV-2 Primer Panel provides optimized, single-day workflows to prepare libraries for sequencing as researchers use NGS to track viral genome changes in studying the epidemiology of virus outbreaks. The two-step process uses advanced QIAseq technologies to conduct reverse transcription and cDNA synthesis from a viral RNA sample, then generate libraries compatible with Illumina sequencing platforms. The workflow is faster and has lower-input requirements compared to hybrid capture solutions.

Please find the full press release here

For an overview of QIAGEN’s coronavirus testing solutions, please visit http://www.qiagen.com/coronavirus.

To explore QIAGEN’s NGS-specific solutions for COVID-19 research, please visit https://go.qiagen.com/CoronavirusNGS

For details of QIAGEN’s SARS-CoV-2 Whole Genome Sequencing Service, please visit https://www.qiagen.com/applications/genomic-services/sars-cov-2-whole-genome-sequencing-services

View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005643/en/

Contacts

QIAGEN
Investor Relations
John Gilardi
+49 2103 29 11711

Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826

Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com